U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07946575) titled 'A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants' on Nov. 12.
Brief Summary: The primary purpose of this study is to evaluate the effect of quinidine sulfate on the pharmacokinetics (PK) of NAL ER in healthy participants.
Study Start Date: Nov. 03
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: NAL ER
Oral tablets
DRUG: Quinidine Sulfate
Oral tablets
Recruitment Status: RECRUITING
Sponsor: Trevi Therapeutics
Published by HT Digital Content Services with permission from Health Daily Digest....